CT-388 vs Orforglipron
Comparison of CT-388 (Moderate evidence) and Orforglipron (High evidence).
Last updated: February 12, 2026
Dossier labels summarize each dossier's research scope. They do not establish comparative treatment benefit or safety. Read the comparison below in that context.
CT-388
Dossier overview
Orforglipron
Dossier overview
Overview
CT-388 and Orforglipron are both studied in the peptide research space.
CT-388: A dual GLP-1/GIP receptor agonist acquired by Roche through the $2.
Orforglipron: The first oral small-molecule (non-peptide) GLP-1 receptor agonist.
Evidence Comparison
| Aspect | CT-388 | Orforglipron |
|---|---|---|
| Evidence Level | Moderate | High |
| Human Studies | 6 | 18 |
| Preclinical Studies | 2 | 2 |
| Total Sources | 8 | 20 |
Key Differences
| Aspect | CT-388 | Orforglipron |
|---|---|---|
| Category | Metabolic | Metabolic |
| Evidence Strength | Moderate | High |
| Total Sources | 8 | 20 |
| Human Studies | 6 | 18 |
Summary
- CT-388: Moderate evidence with 8 total sources (6 human)
- Orforglipron: High evidence with 20 total sources (18 human)
This comparison is for educational purposes only and is not medical advice. Consult a healthcare professional before making any decisions about peptide use.
View Full Dossiers
Stay Updated on Peptide Comparisons
Get notified when we publish new comparison dossiers and evidence reviews.
No spam. Unsubscribe anytime.
Disclaimer: This comparison is for educational purposes only and does not constitute medical advice. Individual responses to medications vary. Always consult a qualified healthcare provider before making treatment decisions.